Impact of rosiglitazone treatment on the bioavailability of antiretroviral compounds in HIV-positive patients

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 2, 2005, Pages 416-419

  Oette, M ^a   Kurowski, M ^b   Feldt, T ^a   Kroidl, A ^a   Sagir, A ^a   Vogt, C ^a   Wettstein, M ^a   Haussinger D ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Vivantes Auguste Viktoria Klinikum   (Germany)

Author keywords

Drug interactions; Glitazones; HAART; Therapeutic drug monitoring

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ROSIGLITAZONE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; GEOMETRY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; OPEN STUDY; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; THIAZOLIDINEDIONES; VIRAL LOAD;

EID: 23844517547     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki234     Document Type: Article

References (10)

1. Carr A, Samaras K, Thorisdottir A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet 1999; 353: 2093-9.
2. Heath KV, Hogg RS, Chan KJ et al. Lipodystrophy-associated morphological, cholesterol and triglycerides abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15: 231-9.
3. Kannisto K, Sutinen J, Korsheninnikova E et al. Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6, and CD 45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17, 1753-62.
4. Caron M, Auclair M, Vigouroux C et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 2001; 50: 1378-88.
5. Miyazaki Y, Mahankali A, Matsuda M et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-91.
6. Carr A, Workman C, Carey D et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: Randomised, double-blind, placebo-controlled trial. Lancet 2004; 63: 429-38.
7. Hadigan C, Yawetz S, Thomas A et al. Metabolic effects of rosiglitazone in HIV lipodystrophy. Ann Intern Med 2004; 140: 786-94.
8. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424-32.
9. Sahi J, Black CB, Hamilton GA et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos 2003; 31: 439-46.
10. Boffito M, Kurowski M, Kruse G et al. Atazanavir enhances saquinavir hard-gel contentrations in a ritonavir-boosted once-daily regimen. AIDS 2004; 18: 1291-7.